Your blog category
CSM Technologies, a leading digital transformation and GovTech company, has filed its draft IPO papers with SEBI to raise funds through a fresh issue of equity shares. Here’s what Indian investors need to know.
Glenmark, Granules India, Zydus, and other Indian drugmakers are recalling products in the US market due to manufacturing issues. Find out what this means for investors and the Indian pharmaceutical industry.
GEE Ltd, Paushak Ltd, and Shilpa Medicare Ltd are set to disburse bonus shares to their stakeholders. Find out the record date, bonus share ratio, and eligibility criteria for these companies.
The Nifty has been experiencing a sell-off, culminating in a decisive bloodbath on Friday. Understand the current market trend and what it means for investors.
Dhariwal Buildtech Ltd. has filed its draft red herring prospectus (DRHP) with SEBI to raise up to Rs 950 crore through an initial public offering (IPO) of fresh equity shares, aiming to fuel its growth initiatives in the infrastructure sector.
Tata Motors’ long-awaited demerger into commercial vehicle and passenger vehicle businesses takes effect on October 1. Here’s what Indian investors need to know about the record date, shareholder ratio, and more.
Waaree Energies, a leading Indian solar module manufacturer, has stated that the ongoing US investigation into potential solar tariff evasion will not impact its investment plans, including the expansion of its Texas facility and setting up a solar cell manufacturing capability in the US.
HDFC Capital-backed Reloy expects 75% revenue growth in FY26, driven by strong demand for housing properties and its innovative referral sales model. Here’s what Indian investors and traders should know about this proptech startup’s growth prospects.
The imposition of a 100% tariff by the US on imports of branded and patented pharmaceutical products is expected to have a limited impact on Indian drug makers, with Sun Pharma being the most exposed to headline risk.
Mid-size Indian IT companies are expected to perform better than their larger peers despite the uncertainty surrounding US visas, according to Vikas Khemani, founder and chief investment officer at Carnelian Asset Management.